Targeting protein kinases in cancer therapy: a success? (Q35987779)

11 August 2017

1 reference

title

Targeting protein kinases in cancer therapy: a success? (English)

1 reference

11 August 2017

Mark A Pearson

1 reference

11 August 2017

Doriano Fabbro

series ordinal

1 reference

11 August 2017

publication date

1 December 2004

1 reference

Expert Review of Anticancer Therapy

11 August 2017

published in

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

11 August 2017

page(s)

1113-1124

1 reference

Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Identification of Src transformation fingerprint in human colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

CDK inhibitors in clinical development for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Protein kinase inhibitors: insights into drug design from structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

The conformational plasticity of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

KIT mutations are common in testicular seminomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Imatinib for systemic mast-cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Resistance to targeted therapy in leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Structure, function and transforming potential of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Clinical cardiac tolerability of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Issues and progress with protein kinase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Targeting epidermal growth factor receptor--are we missing the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Epidermal growth factor receptor inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1113

10.1586/14737140.4.6.1113

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference